KR102674230B1 - 고칼륨혈증의 치료를 위한 조성물 및 방법 - Google Patents

고칼륨혈증의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102674230B1
KR102674230B1 KR1020177019904A KR20177019904A KR102674230B1 KR 102674230 B1 KR102674230 B1 KR 102674230B1 KR 1020177019904 A KR1020177019904 A KR 1020177019904A KR 20177019904 A KR20177019904 A KR 20177019904A KR 102674230 B1 KR102674230 B1 KR 102674230B1
Authority
KR
South Korea
Prior art keywords
delete delete
another embodiment
pharmaceutical composition
composition comprises
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177019904A
Other languages
English (en)
Korean (ko)
Other versions
KR20170098259A (ko
Inventor
도미니크 차모트
제임스 피. 데이비드슨
팽글링 린
제프리 더블유. 제이콥스
나탈리아 브리노바
에릭 라본테
잉그리드 랑세트모
로버트 씨. 블랭크스
Original Assignee
알데릭스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알데릭스, 인코포레이티드 filed Critical 알데릭스, 인코포레이티드
Publication of KR20170098259A publication Critical patent/KR20170098259A/ko
Application granted granted Critical
Publication of KR102674230B1 publication Critical patent/KR102674230B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16—Organic material
    • B01J39/18—Macromolecular compounds
    • B01J39/20—Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F212/02—Monomers containing only one unsaturated aliphatic radical
    • C08F212/04—Monomers containing only one unsaturated aliphatic radical containing one ring
    • C08F212/06—Hydrocarbons
    • C08F212/08—Styrene
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F212/02—Monomers containing only one unsaturated aliphatic radical
    • C08F212/04—Monomers containing only one unsaturated aliphatic radical containing one ring
    • C08F212/14—Monomers containing only one unsaturated aliphatic radical containing one ring substituted by heteroatoms or groups containing heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/22—Esters containing halogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F257/00—Macromolecular compounds obtained by polymerising monomers on to polymers of aromatic monomers as defined in group C08F12/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/34—Introducing sulfur atoms or sulfur-containing groups
    • C08F8/36—Sulfonation; Sulfation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/44—Preparation of metal salts or ammonium salts
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2800/00—Copolymer characterised by the proportions of the comonomers expressed
    • C08F2800/10—Copolymer characterised by the proportions of the comonomers expressed as molar percentages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicinal Preparation (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
KR1020177019904A 2014-12-23 2015-12-22 고칼륨혈증의 치료를 위한 조성물 및 방법 Active KR102674230B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096447P 2014-12-23 2014-12-23
US62/096,447 2014-12-23
PCT/US2015/067460 WO2016111855A1 (en) 2014-12-23 2015-12-22 Compositions and methods for treating hyperkalemia

Publications (2)

Publication Number Publication Date
KR20170098259A KR20170098259A (ko) 2017-08-29
KR102674230B1 true KR102674230B1 (ko) 2024-06-11

Family

ID=55229846

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177019904A Active KR102674230B1 (ko) 2014-12-23 2015-12-22 고칼륨혈증의 치료를 위한 조성물 및 방법

Country Status (17)

Country Link
US (2) US9655921B2 (https=)
EP (1) EP3236940B1 (https=)
JP (3) JP6821571B2 (https=)
KR (1) KR102674230B1 (https=)
CN (1) CN107406548B (https=)
AR (1) AR103250A1 (https=)
AU (1) AU2015375390B2 (https=)
BR (1) BR112017013264A2 (https=)
CA (1) CA2971725C (https=)
ES (1) ES2800167T3 (https=)
IL (1) IL252603A0 (https=)
MX (1) MX373216B (https=)
NZ (1) NZ732542A (https=)
RU (1) RU2017126229A (https=)
TW (1) TW201628631A (https=)
WO (1) WO2016111855A1 (https=)
ZA (1) ZA201703771B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9545425B2 (en) 2014-12-23 2017-01-17 Ardelyx, Inc. Pharmaceutical compositions for treating hyperkalemia
TW201628631A (zh) * 2014-12-23 2016-08-16 亞德利克斯公司 用於治療高血鉀症之組合物及方法
CN118440135A (zh) 2017-08-04 2024-08-06 阿德利克斯股份有限公司 用于治疗高钾血症的甘草次酸衍生物
KR20260004570A (ko) 2019-02-07 2026-01-08 알데릭스, 인코포레이티드 고칼륨혈증 치료에 사용하기 위한 글리시레틴산 유도체
US12280144B2 (en) 2019-12-19 2025-04-22 Zaki Yusuf Gel compositions for mitigation of burn injuries, kits containing the gel compositions, and associated methods
US20240139234A1 (en) * 2021-11-17 2024-05-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Pharmaceutical polymer for treating hyperkalemia and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120309707A1 (en) 2009-12-29 2012-12-06 Universidad Autonoma De Madrid Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3785864A (en) 1970-07-23 1974-01-15 Boehringer Mannheim Gmbh Process for the chromatographic separation of multi-component mixtures containing glucose
GB1561395A (en) * 1976-02-26 1980-02-20 Beecham Group Ltd -lactam antibiotic
CA1166413A (en) 1980-10-30 1984-05-01 Edward E. Timm Process and apparatus for preparing uniform size polymer beads
JPS57193414A (en) * 1981-05-25 1982-11-27 Sekisui Chem Co Ltd Preparation of remedy for hypercalcemia
WO1999020285A1 (en) 1997-10-16 1999-04-29 Sanwa Kagaku Kenkyusho Co., Ltd. Gel preparations containing polystyrenesulfonate
JP3596742B2 (ja) * 1998-07-31 2004-12-02 日研化学株式会社 陽イオン交換樹脂製剤
KR100440544B1 (ko) * 1998-07-31 2004-07-15 니켄 가가쿠 가부시키가이샤 양이온 교환수지 제제
US6270755B1 (en) * 1999-05-13 2001-08-07 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders
BRPI0509331B8 (pt) * 2004-03-30 2021-05-25 Ilypsa Inc uso de uma composição de ligação de sódio
PT2184059E (pt) * 2004-03-30 2012-07-06 Relypsa Inc Polímeros de ligação a ião e seus usos
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
WO2008039358A2 (en) * 2006-09-30 2008-04-03 Capricorn Pharma Inc. Resin-complex granulation for water-soluble drugs and associated methods
DE102007050971B4 (de) * 2007-03-14 2014-12-31 BLüCHER GMBH Verfahren zur Herstellung von Hochleistungsadsorbentien auf der Basis von Aktivkohle mit hoher Meso- und Makroporosität, Hochleistungsadsorbentien und deren Verwendung
MX389664B (es) * 2008-08-22 2025-03-20 Vifor Int Ltd Polimeros reticulados de intercambio cationico, composiciones y su uso en el tratamiento de la hipercalcemia
US20100104527A1 (en) * 2008-08-22 2010-04-29 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US20110028412A1 (en) 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
CA2824441A1 (en) * 2011-01-10 2012-07-19 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation - binding polymers and calcium and/or magnesium cations, and uses thereof
TWI605837B (zh) 2011-01-27 2017-11-21 Kowa Co Ltd Pharmaceutical composition containing water-insoluble drug and pharmaceutical preparation
ES2441468B1 (es) * 2012-08-03 2014-11-13 Laboratorios Rubió, S.A. Composición farmacéutica sólida de resina de intercambio catiónico.
ES2471340B1 (es) * 2012-12-21 2015-08-17 Laboratorios Rubió, S.A. Composición farmacéutica oral para fármacos de elevada posología
TW201628631A (zh) * 2014-12-23 2016-08-16 亞德利克斯公司 用於治療高血鉀症之組合物及方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120309707A1 (en) 2009-12-29 2012-12-06 Universidad Autonoma De Madrid Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases

Also Published As

Publication number Publication date
MX2017007603A (es) 2017-10-19
ZA201703771B (en) 2020-11-25
EP3236940A1 (en) 2017-11-01
WO2016111855A1 (en) 2016-07-14
US20160346318A1 (en) 2016-12-01
CA2971725A1 (en) 2016-07-14
IL252603A0 (en) 2017-07-31
CN107406548B (zh) 2021-03-02
NZ732542A (en) 2023-02-24
JP2023027355A (ja) 2023-03-01
JP6821571B2 (ja) 2021-01-27
EP3236940B1 (en) 2020-02-05
AR103250A1 (es) 2017-04-26
JP2020172662A (ja) 2020-10-22
US9655921B2 (en) 2017-05-23
BR112017013264A2 (pt) 2018-02-27
CN107406548A (zh) 2017-11-28
MX373216B (es) 2020-05-07
JP2018505262A (ja) 2018-02-22
RU2017126229A (ru) 2019-01-28
AU2015375390A1 (en) 2017-06-29
CA2971725C (en) 2024-05-14
US20180064751A1 (en) 2018-03-08
ES2800167T3 (es) 2020-12-28
KR20170098259A (ko) 2017-08-29
TW201628631A (zh) 2016-08-16
JP7254748B2 (ja) 2023-04-10
AU2015375390B2 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
KR102674230B1 (ko) 고칼륨혈증의 치료를 위한 조성물 및 방법
US7776319B2 (en) Methods and compositions for treatment of ion imbalances
US8147873B2 (en) Methods and compositions for treatment of ion imbalances
AU2018256550B2 (en) Compositions comprising crossed linked cation-binding polymers
JP2012176992A (ja) 架橋シェルを有するコア−シェルコンポジットを製造する方法および該方法によって生じたコア−シェルコンポジット
AU2018206706A1 (en) Ion binding polymers and uses thereof
US9867848B2 (en) Compositions and methods for treating hyperkalemia
JP2011506449A (ja) コーティング医薬組成物
HK1246163A1 (en) Compositions and methods for treating hyperkalemia
HK1246163B (en) Compositions and methods for treating hyperkalemia

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170717

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201222

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220819

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230603

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240312

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240605

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240607

End annual number: 3

Start annual number: 1

PG1601 Publication of registration